CAS: 1207753-03-4; (1S,2R,3R,4Ar,6As,7R,8R,10Ar,10Br,12Ar)-2-((R)-2-Amino-2,3,3-Trimethylbutoxy)-1,6A,8,10A-Tetramethyl-8-((R)-3-Methylbutan-2-yl)-3-(5-(Pyridin-4-yl)-1H-1,2,4-Triazol-1-yl)-1,3,4,6,6A,7,8,9,10,10A,10B,11,12,12A-Tetradecahydro-2H-1,4A-(Methanooxymethano)Chrysene-7-Carboxylic Acid

上下游产品

(1S,4Ar,6As,7R,8R,10Ar,10Br,12Ar,14R,15R)-15-[[(2R)-2-Amino-2,3,3-Trimethylbutyl]Oxy]-14-(5-Bromo-1H-1,2,4-Triazol-1-yl)-8-[(1R)-1,2-Dimethylpropyl]-1,6,6A,7,8,9,10,10A,10B,11,12,12A-Dodecahydro-1,6A,8,10A-Tetramethyl-4H-1,4A-Propano-2H-Phenanthro[1,2-C]Pyran-7-Carboxylic Acid 1207751-34-5
Benzyl (1S,4Ar,6As,7R,8R,10Ar,10Br,12Ar,14R,15R)-8-[(1R)-1,2-Dimethylpropyl]-14-Methoxy-15-[[(2R)-2,3,3-Trimethyl-2-[[(4-Methylphenyl)Sulfonyl]Amino]Butyl]Oxy]-1,6,6A,7,8,9,10,10A,10B,11,12,12A-Dodecahydro-1,6A,8,10A-Tetramethyl-4H-1,4A-Propano-2H-Phenanthro[1,2-C]Pyran-7-Carboxylate 1207755-36-9
(1S,4Ar,6As,7R,8R,10Ar,10Br,12Ar,14R,15R)-15-[[(2R)-2-Amino-2,3,3-Trimethylbutyl]Oxy]-8-[(1R)-1,2-Dimethylpropyl]-14-Hydrazino-1,6,6A,7,8,9,10,10A,10B,11,12,12A-Dodecahydro-1,6A,8,10A-Tetramethyl-4H-1,4A-Propano-2H-Phenanthro[1,2-C]Pyran-7-Carboxylic Acid 1207755-65-4
(1S,4Ar,6As,7R,8R,10Ar,10Br,12Ar,14R,15R)-15-[[(2R)-2-Amino-2,3,3-Trimethylbutyl]Oxy]-8-[(1R)-1,2-Dimethylpropyl]-14-Methoxy-1,6,6A,7,8,9,10,10A,10B,11,12,12A-Dodecahydro-1,6A,8,10A-Tetramethyl-4H-1,4A-Propano-2H-Phenanthro[1,2-C]Pyran-7-Carboxylic Acid 1207755-38-1

4-吡啶甲酰胺置于碳酸氢钠,溶剂黄146体系中,用 乙酸乙酯 用作溶剂,化学反应 2.75H,反应生成艾瑞芬净
参考文献:Ibrexafungerp:一种具有口服活性的 β-1,3-葡聚糖合成抑制剂
标题:Ibrexafungerp:一种具有口服活性的 β-1,3-葡聚糖合成抑制剂
摘要:我们之前报道了确定 Mk-5204 的药物化学工作,Mk-5204 是一种口服有效的 β-1,3-葡聚糖合成抑制剂,来源于天然产物恩夫马芬净.C2 三唑取代基的进一步优化确定 4-吡啶基是 Mk-5204 甲酰胺的首选替代品,导致在血清存在下的抗真菌活性提高,并增加口服暴露.在这个新发现的 C2 取代基的存在下重新优化 C3 处的氨基醚,证实(R) Mk-5204 的叔丁基甲基氨基醚提供了这两个关键参数的最佳平衡,最终发现了 Ibrexafungerp,目前正处于 Iii 期临床试验.Ibrexafungerp 在小鼠感染模型中显示出显着改善的口服功效,使其成为临床开发的优秀候选药物,作为念珠菌和曲霉菌感染的口服治疗药物.
Doi:10.1016/j.Bmcl.2020.127661

专利信息

专利号:WO-2025201218-A1
优先权日:2024-03-25
标题 :Synthetic gene cluster of enfumafungin antibiotic and synthesis method therefor
发明人：GAO HAO; HU DAN; WANG GAOQIAN; LV JIANMING; CHEN GUODONG; WANG CHUANXI; CAO ZHIQIN
权利人:UNIV JINAN
摘要:The present invention relates to a synthetic gene cluster of an enfumafungin antibiotic and a synthetic method therefor. Specifically, in the present invention, key functional genes in the linking of a β-D-glucopyranose at position C3 of a fernane-type framework, the oxidation at position C2 into α-OH, the oxidative cleavage of ring E at C19-C20, and the acetylation of hydroxyl at position C2 during the biosynthesis of an enfumafungin antibiotic, i.e. fuscoatroside, are isolated, wherein the genes are named fsoA, fsoD, fsoE and fsoF, respectively. The present invention also provides encoding polypeptides thereof. Provided in the present invention are an artificial fusion enzyme gene, i.e. efuA (TC) fsoA (GT) ; and on the basis of the artificial fusion enzyme gene, the heterologous expression of four genes, i.e. efuA (TC) fsoA (GT) , fsoD, fsoE and fsoF, can synthesize an enfumafungin precursor (13). The present invention clarifies an FsoE-mediated C-C bond breaking function of a P450 enzyme, and provides a key catalytically active residue of FsoE. The present invention reports the biosynthetic pathway of such compound for the first time, and establishes an important foundation for the green and efficient synthesis of the compound.

专利号:US-11534433-B2
优先权日:2017-08-04
标 题 :Antifungal agents with enhanced activity in acidic pH
发明人：ANGULO GONZALEZ DAVID A
权利人:SCYNEXIS INC
摘要:Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such conditions. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of yeast or mold infections that occur in anatomic areas having a low pH, such as the vaginal cavity, or under acidic local environment conditions such of those seen in fungal abscesses, empyema, or upper gastrointestinal tract infections.

专利号:US-11110102-B2
优先权日:2017-04-10
标题 :Antifungal agents used in combination
发明人：ANGULO GONZALEZ DAVID A
权利人:SCYNEXIS INC
摘要:The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds in combination with other antifungal agents such azoles, polyenes, lipopeptides, and allylamides to treat fungal diseases. More particularly, the invention relates to antifungal combinations of enfumafungin derivative triterpenoids which are inhibitors of (1,3)-β-D-glucan synthesis, in combination with other antifungal agents such as mold-active agents that have activity against molds, including but not limited to voriconazole, isavuconazole, posaconazole, itraconazole and amphotericin B, for the treatment and/or prevention of infections caused by molds.